# Standard BioTools Inc. (LAB) ROE: -17.7% in 2025

URL: https://funkfolio.com/stock/LAB/roe

> Standard BioTools Inc. (LAB) return on equity (ROE) was -17.7% in fiscal 2025, up 11.8 points from fiscal 2024. Its median over 12 fiscal years is -40.8%.

---

## Standard BioTools Inc. (LAB) return on equity (ROE)

**Return on equity · fiscal 2025:** -17.7% year ended Dec 31, 2025

Standard BioTools Inc. (LAB) earned a return on equity of -17.7% in fiscal 2025 (the year ended December 31, 2025). That is 11.8 percentage points higher than the -29.4% of fiscal 2024. Figures as of 17 Nov 2026, 17:30 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **Return on equity, fiscal 2025:** -17.7%
- **Change on fiscal 2024:** +11.8 pts
- **Highest on record:** -17.1% fiscal 2013
- **Lowest on record:** -195.7% fiscal 2017
- **Fiscal years on record:** 13 2011–2025

Figures as of 17 Nov 2026, 17:30 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

### Standard BioTools Inc. return on equity (ROE), in more detail

Across the 13 fiscal years on record (2011–2025), the highest was -17.1% in fiscal 2013 and the lowest -195.7% in fiscal 2017. The fiscal 2025 figure is higher than in 92% of the 12 earlier fiscal years on record, whose median is -40.8%.

### Return on equity by fiscal year

### Standard BioTools Inc. return on equity (ROE), year by year

Standard BioTools Inc. (LAB) return on equity (ROE) by fiscal year

| Fiscal year | Return on equity | Change | Year ended |
| --- | --- | --- | --- |
| 2025 | -17.7% | 11.8 pts up | Dec 31, 2025 |
| 2024 | -29.4% | — | Dec 31, 2024 |
| 2021 | -62.6% | 24.5 pts down | Dec 31, 2021 |
| 2020 | -38.1% | 4.0 pts up | Dec 31, 2020 |
| 2019 | -42.2% | 39.7 pts up | Dec 31, 2019 |
| 2018 | -81.8% | 113.9 pts up | Dec 31, 2018 |
| 2017 | -195.7% | 52.9 pts down | Dec 31, 2017 |
| 2016 | -142.7% | 96.3 pts down | Dec 31, 2016 |
| 2015 | -46.4% | 11.3 pts down | Dec 31, 2015 |
| 2014 | -35.1% | 18.0 pts down | Dec 31, 2014 |
| 2013 | -17.1% | 1.8 pts up | Dec 31, 2013 |
| 2012 | -18.9% | 20.6 pts up | Dec 31, 2012 |
| 2011 | -39.5% | — | Dec 31, 2011 |

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

### How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

### Standard BioTools Inc., figure by figure

- [Standard BioTools Inc. market cap](https://funkfolio.com/stock/LAB/market-cap)
- [Standard BioTools Inc. revenue](https://funkfolio.com/stock/LAB/revenue)
- [Standard BioTools Inc. earnings](https://funkfolio.com/stock/LAB/earnings)
- [Standard BioTools Inc. earnings per share (EPS)](https://funkfolio.com/stock/LAB/eps)
- [Standard BioTools Inc. P/E ratio](https://funkfolio.com/stock/LAB/pe-ratio)
- [Standard BioTools Inc. P/S ratio](https://funkfolio.com/stock/LAB/ps-ratio)
- [Standard BioTools Inc. P/B ratio](https://funkfolio.com/stock/LAB/pb-ratio)
- [Standard BioTools Inc. free cash flow](https://funkfolio.com/stock/LAB/free-cash-flow)
- [Standard BioTools Inc. operating margin](https://funkfolio.com/stock/LAB/operating-margin)
- [Standard BioTools Inc. dividend](https://funkfolio.com/stock/LAB/dividend)
- [Standard BioTools Inc. shares outstanding](https://funkfolio.com/stock/LAB/shares-outstanding)
- [Standard BioTools Inc. total debt](https://funkfolio.com/stock/LAB/total-debt)
- [Standard BioTools Inc. cash on hand](https://funkfolio.com/stock/LAB/cash)
- [Standard BioTools Inc. total assets](https://funkfolio.com/stock/LAB/total-assets)
- [Standard BioTools Inc. return on invested capital (ROIC)](https://funkfolio.com/stock/LAB/roic)

[Standard BioTools Inc. (LAB) overview: price, valuation and scorecard](https://funkfolio.com/stock/LAB)

### Standard BioTools Inc. return on equity (ROE): questions and answers

**What is Standard BioTools Inc.'s return on equity?**

Standard BioTools Inc. (LAB) earned a return on equity of -17.7% in fiscal 2025 (the year ended December 31, 2025). That is 11.8 percentage points higher than the -29.4% of fiscal 2024.

**Is Standard BioTools Inc.'s return on equity high or low compared with its own history?**

The fiscal 2025 figure is higher than in 92% of the 12 earlier fiscal years on record, whose median is -40.8%.

**What are the highest and lowest return on equity figures on record for Standard BioTools Inc.?**

Across the 13 fiscal years on record (2011–2025), the highest was -17.1% in fiscal 2013 and the lowest -195.7% in fiscal 2017.

**How is Standard BioTools Inc.'s return on equity calculated?**

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

### Learn: return on equity (ROE)

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Return on invested capital (ROIC) vs ROE and ROA](https://funkfolio.com/learn/stocks/return-on-invested-capital)

  Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.

### Cite this page

Funkfolio, “Standard BioTools Inc. (LAB) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/LAB/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.
